Acutaas ChemicalQ3 FY24

Acutaas Chemical Q3 FY24 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹3,942.9P/E: 73.5Market Cap: ₹32.3K CrSector: Pharmaceuticals & Biotechnology

Management growth scorecard

Revenue

Category 3

Margin

Category 1

Fundraise

Yes

Order

N/A

Capex

Yes

3 of 4 growth signals are positive.

Full analysis

Revenue guidance

Category 3
  • Revenue growth guidance for FY24 is revised to 15-18%, down from earlier 18-22% due to pricing erosion.
  • For FY25, revenue growth is expected between 17-22%, driven by ramp-up in Fermion contract, new electrolyte products, and other projects.
  • Volume growth has been strong at 25% year-on-year, indicating robust business traction despite pricing pressures.
  • The company plans to achieve Rs. 1,000 crore revenue target by mid-FY26.
  • Electrolyte additives supply has commenced commercially with long-term contracts signed; capacity expansion planned from 500 MT to 2,000 MT.
  • New Ankleshwar plant inauguration and partnerships (e.g., with Fermion) expected to boost higher-value advanced intermediates production.
  • Expansion in Specialty Chemical and Pharma Intermediate segments with product ramp-ups expected from Q1 FY25.
  • Rs. 300 crore CAPEX underway (e.g., for electrolyte and Ankleshwar facility upgrades) to enable future growth.

See what Acutaas Chemical management said on margin guidance — free account, 30 seconds.

Fundraise plans

Yes
  • Ami Organics has taken Rs. 119 crores of debt to fund the Ankleshwar facility capex.
  • The total capex outlay for the Ankleshwar unit was revised upwards from Rs. 190 crores to Rs. 310 crores, involving additional machinery and infrastructure for a CDMO contract.
  • The company plans to fund capex through a mix of internal accruals and debt; no mention of fresh equity fundraising was made.
  • Finance cost for Q3 was Rs. 25 million and is expected to be similar or slightly higher next quarter due to additional capex borrowings.
  • The overall debt-to-equity ratio after the recent debt is around 63% debt and 37% equity, indicating no immediate plans for equity dilution.
  • No explicit future plans for new fundraising (debt or equity) beyond these were discussed in the call.

See what Acutaas Chemical management said on order book — free account, 30 seconds.

Capex plans

Yes
  • Total capex outlay for Ankleshwar unit revised from Rs. 190 crores to Rs. 310 crores due to additional machinery for CDMO contract and allied infrastructure.
  • Rs. 119 crores debt taken to fund this capex, with overall funding through a mix of internal accruals and debt.
  • Ankleshwar facility upgradation ongoing and expected to complete soon.
  • Rs. 300 crores capex planned, mostly for electrolyte business, but deployment will take some time.
  • Ankleshwar facility expected to have a turnover of 3-3.5x the asset value post-upgrade.
  • No capital infusion planned currently for Baba Fine Chemicals acquisition; it is an established business.
  • Capacity expansion planned for electrolyte additives: from current 500 metric tons each to an additional 2,000 metric tons each.
  • Electrolyte CDMO business is CAPEX intensive with standard multi-year ramp-up timeline.

Track Acutaas Chemical — get its next earnings analysis in your feed

How does Acutaas Chemical rank vs peers in Pharmaceuticals & Biotechnology?

Pro feature
ThisAcutaas Chemical
Rev 3Mar 1

How does Acutaas Chemical rank in Pharmaceuticals & Biotechnology?

Compare Acutaas Chemical against every Pharmaceuticals & Biotechnology company (Q3 FY24) on revenue, margins and earnings-call signals.

View Pharmaceuticals & Biotechnology leaderboard →

Others in Pharmaceuticals & Biotechnology this season

  • Lasa Supergeneri (Q2 FY27)

    306.11 Lakhs in Q2 Sept 30, 2025 (over 99% decline YoY). Key results statement takeaways from Lasa Supergenerics Ltd's Q2 FY27 results statement — and how it ra

  • Themis Medicare (Q2 FY27)

    Q2 FY27 net revenue: ₹89.74 crore, up 15.1% year-on-year from ₹77.99 crore in Q2 FY26 (Page 8). Key investor presentation takeaways from Themis Medicare Ltd's Q

  • Panacea Biotec (Q2 FY27)

    September 30, 2026: ₹18,967 Lakh . Key results statement takeaways from Panacea Biotec Ltd's Q2 FY27 results statement — and how it ranks against sector peers.

  • Biofil Chemicals (Q2 FY27)

    Quarterly Revenue (Q2 ended 30/09/2026):** ₹166.87 Lakhs (Pharma Unit), ₹0.00 Lakhs (Chemicals Division); Total Gross Turnover ₹166.87 Lakhs. Key results statem

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →